Anti COVID-19 Convalescent Plasma Therapy
Sponsor: Humán Bioplazma Kft - Kedrion
Listed as NCT04345679, this EARLY_PHASE1 trial focuses on COVID 19 and remains ongoing. Sponsored by Humán Bioplazma Kft - Kedrion, it has been updated 6 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown EARLY_PHASE1
Status: Unknown Status → Unknown
-
Mar 2023 — Jul 2024 [monthly]
Unknown Status EARLY_PHASE1
Status: Recruiting → Unknown Status
-
Mar 2021 — Mar 2023 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
▶ Show 1 earlier version
-
May 2020 — Jan 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Humán Bioplazma Kft - Kedrion
- Hungarian National Blood Service
- Orthosera Kft.
- Semmelweis University
- University of Pecs
For direct contact, visit the study record on ClinicalTrials.gov .